Should I buy or sell AngioDynamics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANGO shares. View ANGO analyst ratings or view top-rated stocks .

What is AngioDynamics' stock price target for 2024?

4 brokers have issued 1 year target prices for AngioDynamics' shares. Their ANGO share price targets range from $10.00 to $18.00. On average, they expect the company's share price to reach $14.25 in the next year. This suggests a possible upside of 132.8% from the stock's current price. View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts .

How have ANGO shares performed in 2024?

AngioDynamics' stock was trading at $7.84 at the beginning of the year. Since then, ANGO stock has decreased by 21.9% and is now trading at $6.12. View the best growth stocks for 2024 here .

Are investors shorting AngioDynamics?

AngioDynamics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 2,250,000 shares, a drop of 8.5% from the March 15th total of 2,460,000 shares. Based on an average trading volume of 575,400 shares, the short-interest ratio is currently 3.9 days. View AngioDynamics' Short Interest .

When is AngioDynamics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024. View our ANGO earnings forecast .

How were AngioDynamics' earnings last quarter?

AngioDynamics, Inc. (NASDAQ:ANGO) released its earnings results on Wednesday, July, 12th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The medical instruments supplier had revenue of $91.10 million for the quarter, compared to analysts' expectations of $90.73 million. AngioDynamics had a negative trailing twelve-month return on equity of 3.48% and a negative net margin of 60.21%. The firm's quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the firm earned $0.01 EPS.

What ETF holds AngioDynamics' stock?

Invesco Nasdaq Future Gen 200 ETF holds 7,477 shares of ANGO stock, representing 0.65% of its portfolio.

What guidance has AngioDynamics issued on next quarter's earnings?

AngioDynamics issued an update on its FY 2024 earnings guidance on Thursday, April, 4th. The company provided EPS guidance of -0.580--0.540 for the period, compared to the consensus EPS estimate of -0.430. The company issued revenue guidance of $270.0 million-$275.0 million, compared to the consensus revenue estimate of $312.1 million.

What is James C. Clemmer's approval rating as AngioDynamics' CEO?

34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com . James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.

What other stocks do shareholders of AngioDynamics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE) , Intel (INTC) , Oasis Petroleum (OAS) , Advanced Micro Devices (AMD) , Freeport-McMoRan (FCX) , Amicus Therapeutics (FOLD) , Rigel Pharmaceuticals (RIGL) , Accuray (ARAY) , Celldex Therapeutics (CLDX) and Chimerix (CMRX) .

Who are AngioDynamics' major shareholders?

AngioDynamics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Chad Thomas Campbell , Dave Helsel , James C Clemmer , James C Clemmer , Scott Centea , Stephen A Trowbridge and Wesley Johnson. View institutional ownership trends .

How do I buy shares of AngioDynamics?

Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does AngioDynamics have any subsidiaries?

The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical. Read More

NASDAQ:ANGO

AngioDynamics (ANGO) Stock Price, News & Analysis

→ Now Open: Crypto emergency update (From InvestorPlace) (Ad)

Free ANGO Stock Alerts

$6.12

-0.21 (-3.32%)

(As of 04/18/2024 ET)

Compare

Today's Range: $6.11
▼
$6.38
50-Day Range: $5.27
▼
$7.03
52-Week Range: $5.26
▼
$11.38

Volume: 806,883 shs
Average Volume: 584,395 shs
Market Capitalization: $245.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.25

Get AngioDynamics alerts:

AngioDynamics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 132.8% Upside
$14.25 Price Target
Short Interest: Healthy
5.62% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.99
Upright™ Environmental Score
News Sentiment: 0.90
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$67,000 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($0.57) to ($0.55) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.48 out of 5 stars

Medical Sector

87th out of 918 stocks

Surgical & Medical Instruments Industry

14th out of 91 stocks

3.5

Analyst's Opinion

Consensus Rating
AngioDynamics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
AngioDynamics has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.62% of the outstanding shares of AngioDynamics have been sold short.
Short Interest Ratio / Days to Cover
AngioDynamics has a short interest ratio ("days to cover") of 3.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in AngioDynamics has recently decreased by 8.54%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
AngioDynamics does not currently pay a dividend.
Dividend Growth
AngioDynamics does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
AngioDynamics has received a 59.93% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Ultrasound machines", "Clinical laser systems", and "Intravenous therapy equipment" products. See details.
Environmental Sustainability
The Environmental Impact score for AngioDynamics is -0.99.

2.7

News and Social Media Coverage

News Sentiment
AngioDynamics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for AngioDynamics this week, compared to 3 articles on an average week.
Search Interest
7 people have searched for ANGO on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added AngioDynamics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, AngioDynamics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $67,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 5.10% of the stock of AngioDynamics is held by insiders.
Percentage Held by Institutions
89.43% of the stock of AngioDynamics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for AngioDynamics are expected to grow in the coming year, from ($0.57) to ($0.55) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of AngioDynamics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of AngioDynamics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
AngioDynamics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

You’re invited: Biggest crypto event of 2024

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About AngioDynamics Stock (NASDAQ:ANGO)

AngioDynamics, Inc. provides invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology in the United States and internationally. It offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium for treatment of peripheral arterial disease. The company's thrombus management portfolio includes AlphaVac system, an emergent mechanical aspiration device that eliminates the need for perfusionist support; thrombolytic catheters that are used to deliver thrombolytic agents, which are drugs to dissolve blood clots in hemodialysis access grafts, arteries, veins, and surgical bypass grafts; and AngioVac circuit is indicated for extracorporeal circulatory support for periods of up to six hours including off-the-shelf pump, filter, and reinfusion cannula, to facilitate venous drainage as part of an extracorporeal bypass procedure. In addition, it offers NanoKnife IRE Ablation System, an alternative to traditional thermal ablation for the surgical ablation of soft tissue; and peripheral products, which includes angiographic catheters and diagnostic and interventional guidewires, percutaneous drainage catheters, and coaxial micro-introducer kits used during peripheral diagnostic and interventional procedures. The company also provides drainage catheters for multi-purpose/general, nephrostomy, and biliary drainage; micro Access kits provides interventional physicians a smaller introducer system for minimally invasive procedures; VenaCure EVLT system that are used in endovascular laser procedures to treat superficial venous disease; and Solero MTA System includes solero microwave generator and the specially designed solero MW applicators. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

ANGO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ANGO Stock News Headlines

April 9, 2024 | insidertrades.com

James C. Clemmer Acquires 10,000 Shares of AngioDynamics, Inc. (NASDAQ:ANGO) Stock

April 17, 2024 | finance.yahoo.com

AngioDynamics, Inc. (ANGO) Interactive Stock Chart - Yahoo Finance

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 17, 2024 | americanbankingnews.com

AngioDynamics, Inc. (NASDAQ:ANGO) Short Interest Down 8.5% in March

April 10, 2024 | finance.yahoo.com

Insider Spends US$67k Buying More Shares In AngioDynamics

April 9, 2024 | seekingalpha.com

A Leaner AngioDynamics Is A High-Risk Execution-Driven Story

April 8, 2024 | finance.yahoo.com

AngioDynamics, Inc. (NASDAQ:ANGO) Q3 2024 Earnings Call Transcript

April 6, 2024 | finance.yahoo.com

AngioDynamics Third Quarter 2024 Earnings: Misses Expectations

April 19, 2024 | InvestorPlace (Ad)

Now Open: Crypto emergency update

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

April 6, 2024 | seekingalpha.com

AngioDynamics (ANGO) Q3 2024 Earnings Call Transcript

April 6, 2024 | markets.businessinsider.com

Buy Rating Affirmed for AngioDynamics Amid Strong Sales and Strategic Growth Opportunities

April 6, 2024 | markets.businessinsider.com

Buy Rating Reaffirmed for AngioDynamics Amidst Strategic Growth and Med-Tech Sector Potential

April 5, 2024 | msn.com

AngioDynamics upgraded at Oppenheimer on pipeline progress

April 4, 2024 | finance.yahoo.com

Medical Devices Focused AngioDynamics Unveils Upbeat 2024 Financial Outlook, Stock Soars

April 4, 2024 | marketwatch.com

AngioDynamics Shares Rise 10% After FDA Clears AlphaVac F18 System

April 4, 2024 | markets.businessinsider.com

ANGO Stock Earnings: AngioDynamics Misses EPS, Misses Revenue for Q3 2024

April 4, 2024 | marketwatch.com

AngioDynamics Gets FDA Clearance For Pulmonary Embolism Treatment

April 4, 2024 | marketwatch.com

AngioDynamics Cut Fiscal-Year Revenue Outlook, Reflecting Divestments

April 4, 2024 | sfgate.com

AngioDynamics: Fiscal Q3 Earnings Snapshot

April 4, 2024 | markets.businessinsider.com

AngioDynamics: FDA Clears AlphaVac F1885 System In Treatment Of Pulmonary Embolism

April 4, 2024 | markets.businessinsider.com

AngioDynamics Q3 Loss Sharply Widens; Slashes FY24 Outlook

April 4, 2024 | msn.com

AngioDynamics gets FDA clearance for pulmonary embolism treatment device

April 4, 2024 | businesswire.com

AngioDynamics Reports Fiscal Year 2024 Third Quarter Financial Results; Updates Fiscal Year 2024 Guidance to Reflect Asset Divestiture

April 4, 2024 | businesswire.com

AngioDynamics Receives 510(k) Clearance for AlphaVac F1885 System in Treatment of PE

April 2, 2024 | msn.com

AngioDynamics Resolves Decade-Long Patent Litigation With Becton, Dickinson In Settlement Agreement

April 2, 2024 | markets.businessinsider.com

AngioDynamics Settles All Patent Litigation With C.R. Bard

April 1, 2024 | marketwatch.com

AngioDynamics Settles Multi-Year Patent Dispute with Becton Dickinson & Co

See More Headlines

Receive ANGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AngioDynamics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 7/12/2023
Today: 4/18/2024
Fiscal Year End: 5/31/2024
Next Earnings (Estimated): 7/10/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: Health Care Equipment
Current Symbol: NASDAQ:ANGO
CUSIP: 03475V10
CIK: 1275187
Web: www.angiodynamics.com
Phone: (518) 795-1400
Fax: 518-795-1401
Employees: 815
Year Founded: 1988

Price Target and Rating

Average Stock Price Target: $14.25
High Stock Price Target: $18.00
Low Stock Price Target: $10.00
Potential Upside/Downside: +132.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.84)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-52,440,000.00
Net Margins: -60.21%
Pretax Margin: -61.53%
Return on Equity: -3.48%
Return on Assets: -2.68%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 2.29
Quick Ratio: 1.62

Sales & Book Value

Annual Sales: $338.75 million
Price / Sales: 0.72
Cash Flow: $1.03 per share
Price / Cash Flow: 5.94
Book Value: $5.46 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 40,060,000
Free Float: 38,012,000
Market Cap: $245.17 million
Optionable: Optionable
Beta: 0.66

Social Links

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Mr. James C. Clemmer (Age 60)
CEO, President & Director
Comp: $982.92k
Mr. Stephen A. Trowbridge (Age 50)
Executive VP & CFO
Comp: $528.02k
Mr. Chad T. Campbell (Age 53)
Senior VP and GM of Global Vascular Access & Oncology Global Business Unit
Comp: $416.51k
Ms. Laura Piccinini (Age 55)
Senior VP & GM of International
Comp: $444.31k
Mr. Saleem M. Cheeks
Vice President of Communications
Mr. Benjamin H. Davis (Age 60)
Senior Vice President of Business Development
Ms. Marna I. Bronfen-Moore (Age 57)
Senior Vice President of Human Resources
Mr. Warren G. Nighan (Age 55)
Senior Vice President of Quality & Regulatory Affairs
Comp: $622.11k
Ms. Kim L. Seabury (Age 57)
Senior Vice President of Information Technology
Mr. Juan Carlos Serna
Senior Vice President of Scientific & Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ANGO Stock Analysis - Frequently Asked Questions

Should I buy or sell AngioDynamics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AngioDynamics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ANGO shares.
View ANGO analyst ratings or view top-rated stocks.
What is AngioDynamics' stock price target for 2024?: 4 brokers have issued 1 year target prices for AngioDynamics' shares. Their ANGO share price targets range from $10.00 to $18.00. On average, they expect the company's share price to reach $14.25 in the next year. This suggests a possible upside of 132.8% from the stock's current price.
View analysts price targets for ANGO or view top-rated stocks among Wall Street analysts.
How have ANGO shares performed in 2024?: AngioDynamics' stock was trading at $7.84 at the beginning of the year. Since then, ANGO stock has decreased by 21.9% and is now trading at $6.12.
View the best growth stocks for 2024 here.
Are investors shorting AngioDynamics?: AngioDynamics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 2,250,000 shares, a drop of 8.5% from the March 15th total of 2,460,000 shares. Based on an average trading volume of 575,400 shares, the short-interest ratio is currently 3.9 days.
View AngioDynamics' Short Interest.
When is AngioDynamics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, July 10th 2024.
View our ANGO earnings forecast.
How were AngioDynamics' earnings last quarter?: AngioDynamics, Inc. (NASDAQ:ANGO) released its earnings results on Wednesday, July, 12th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.02. The medical instruments supplier had revenue of $91.10 million for the quarter, compared to analysts' expectations of $90.73 million. AngioDynamics had a negative trailing twelve-month return on equity of 3.48% and a negative net margin of 60.21%. The firm's quarterly revenue was up 4.7% on a year-over-year basis. During the same period last year, the firm earned $0.01 EPS.
What ETF holds AngioDynamics' stock?: Invesco Nasdaq Future Gen 200 ETF holds 7,477 shares of ANGO stock, representing 0.65% of its portfolio.

What guidance has AngioDynamics issued on next quarter's earnings?: AngioDynamics issued an update on its FY 2024 earnings guidance on Thursday, April, 4th. The company provided EPS guidance of -0.580--0.540 for the period, compared to the consensus EPS estimate of -0.430. The company issued revenue guidance of $270.0 million-$275.0 million, compared to the consensus revenue estimate of $312.1 million.
What is James C. Clemmer's approval rating as AngioDynamics' CEO?: 34 employees have rated AngioDynamics Chief Executive Officer James C. Clemmer on Glassdoor.com. James C. Clemmer has an approval rating of 50% among the company's employees. This puts James C. Clemmer in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 47.0% of employees surveyed would recommend working at AngioDynamics to a friend.
What other stocks do shareholders of AngioDynamics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other AngioDynamics investors own include General Electric (GE), Intel (INTC), Oasis Petroleum (OAS), Advanced Micro Devices (AMD), Freeport-McMoRan (FCX), Amicus Therapeutics (FOLD), Rigel Pharmaceuticals (RIGL), Accuray (ARAY), Celldex Therapeutics (CLDX) and Chimerix (CMRX).
Who are AngioDynamics' major shareholders?: AngioDynamics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Chad Thomas Campbell, Dave Helsel, James C Clemmer, James C Clemmer, Scott Centea, Stephen A Trowbridge and Wesley Johnson.
View institutional ownership trends.
How do I buy shares of AngioDynamics?: Shares of ANGO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does AngioDynamics have any subsidiaries?: The following companies are subsidiares of AngioDynamics: AngioDynamics Canada Inc., AngioDynamics France SARL, AngioDynamics Medical Brasil Participacoes Ltda., AngioDynamics Netherlands B. V., AngioDynamics UK Limited, AngioDynamics VA LLC, Clinical Devices, Eximo Medical Ltd., FlowMedica, NM Holding Company Inc., Navilyst Medical Holdings Inc., Navilyst Medical Inc., Oncovionic, RITA Medical Systems, RITA Medical Systems LLC, RadiaDyne LLC, and Vortex Medical.
Read More

This page (NASDAQ:ANGO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

AngioDynamics (ANGO) Stock Price, News & Analysis

AngioDynamics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About AngioDynamics Stock (NASDAQ:ANGO)

ANGO Stock Price History

ANGO Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

ANGO Stock Analysis - Frequently Asked Questions

Overall MarketRank^™